RxDoctor Payments Data

Patrick Goleski, MD

Interventional Cardiology · Seattle, WANPI 1588989032

Payments from drug & device makers

$2,788in general payments, 2019–2025

Across 67 payments — averaging $41.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$245
  • Penumbra, Inc.$188
  • Abbott$183
  • Abiomed$162
  • Shockwave Medical, Inc$60
  • plus $328 from 11 others

What the payments were for

  • Travel & lodging$602%
  • Food & beverage$2,72898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,788 in reported general payments places this provider in the 40th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$331,885
Medicare patients
1,781
Services billed
4,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$197,432
EntrestoSacubitril/Valsartan114$187,291
XareltoRivaroxaban121$160,575
JardianceEmpagliflozin69$81,774
Repatha SureclickEvolocumab73$72,704
BrilintaTicagrelor12$11,461
Metoprolol Succinate287$5,925
Ezetimibe208$5,541
Atorvastatin Calcium339$3,869
ClopidogrelClopidogrel Bisulfate127$2,278
Eplerenone28$1,794
Isosorbide Mononitrate ErIsosorbide Mononitrate91$1,776
Losartan Potassium141$1,387
Rosuvastatin Calcium77$1,305
Ranolazine ErRanolazine12$1,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$197,432150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →